Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

RNA Editing By APOBEC3A Confers Dynamic Mutational Load in Monocytic Leukemias

Bora E Baysal, MD PhD, Shraddha Sharma, PhD, Jianmin Wang, PhD, Eduardo Cortes-Gomez, M.S, Scott Portwood, MS, Eunice S. Wang, MD

Blood (2017) 130 (Supplement 1): 3939.

https://doi.org/10.1182/blood.V130.Suppl_1.3939.3939

Published: 2017

Journal Articles

Inhibition of the Histone Chaperone, FACT (Facilitates Chromatin Transcription) By the Novel Small Molecule CBL0137 (Curaxin) Shows Promising Efficacy in Pre-Clinical Models of Acute Myeloid Leukemia

Scott Portwood, MS, Eunice S. Wang, MD, Alfiya Safina, PhD, Katerina Gurova, MDPhD

Blood (2017) 130 (Supplement 1): 1372.

https://doi.org/10.1182/blood.V130.Suppl_1.1372.1372

Published: 2017

Journal Articles

Combining IMGN779, a Novel Anti-CD33 Antibody-Drug Conjugate (ADC), with the PARP Inhibitor, Olaparib, Results in Enhanced Anti-Tumor Activity in Preclinical Acute Myeloid Leukemia (AML) Models

Scott Portwood, MS, MBA, Robert A Puchalski, Russell M Walker, MS, Eunice S. Wang, MD

Blood (2016) 128 (22): 1645.

https://doi.org/10.1182/blood.V128.22.1645.1645

Published: 2016

Journal Articles

Targeting Innate and Adaptive Immune Responses for the Treatment of Acute Myeloid Leukemia

Amanda Przespolewski, DO, Scott Portwood, MS, MBA, Jason Den Haese, MS, Demi Lewis, Eunice S. Wang, MD

Blood (2016) 128 (22): 2833.

https://doi.org/10.1182/blood.V128.22.2833.2833

Published: 2016

Journal Articles

Functional Genomics and Computational Approaches Identify Novel Small Molecules Targeting Quiescent Leukemia Stem Cells

Costakis Frangou, PhD, Jason Den Haese, PhD, Jordan Warunek, Scott Portwood, MS, MBA, Norma J Nowak, PhD, Andrei V Gudkov, PhD, Katerina Gurova, PhD, Meir Wetzler, MD, Eunice S. Wang, MD

Blood (2015) 126 (23): 1391.

https://doi.org/10.1182/blood.V126.23.1391.1391

Published: 2015

Journal Articles

Optimizing Effects of mTOR Inhibition in Acute Myelogenous Leukemia

Joshua Acklin, Mitra Azadniv, PhD, Scott Portwood, MS, MBA, Kimberly Lacagnina, MA, Charlotte Beers, Eunice S. Wang, MD, Jane L. Liesveld, MD

Blood (2015) 126 (23): 4930.

https://doi.org/10.1182/blood.V126.23.4930.4930

Published: 2015

NARROW

RNA Editing By APOBEC3A Confers Dynamic Mutational Load in Monocytic Leukemias

Inhibition of the Histone Chaperone, FACT (Facilitates Chromatin Transcription) By the Novel Small Molecule CBL0137 (Curaxin) Shows Promising Efficacy in Pre-Clinical Models of Acute Myeloid Leukemia

Combining IMGN779, a Novel Anti-CD33 Antibody-Drug Conjugate (ADC), with the PARP Inhibitor, Olaparib, Results in Enhanced Anti-Tumor Activity in Preclinical Acute Myeloid Leukemia (AML) Models

Targeting Innate and Adaptive Immune Responses for the Treatment of Acute Myeloid Leukemia

Functional Genomics and Computational Approaches Identify Novel Small Molecules Targeting Quiescent Leukemia Stem Cells

Optimizing Effects of mTOR Inhibition in Acute Myelogenous Leukemia

Email alerts

ASH Publications

American Society of Hematology

RNA Editing By APOBEC3A Confers Dynamic Mutational Load in Monocytic Leukemias

Inhibition of the Histone Chaperone, FACT (Facilitates Chromatin Transcription) By the Novel Small Molecule CBL0137 (Curaxin) Shows Promising Efficacy in Pre-Clinical Models of Acute Myeloid Leukemia

Combining IMGN779, a Novel Anti-CD33 Antibody-Drug Conjugate (ADC), with the PARP Inhibitor, Olaparib, Results in Enhanced Anti-Tumor Activity in Preclinical Acute Myeloid Leukemia (AML) Models

Targeting Innate and Adaptive Immune Responses for the Treatment of Acute Myeloid Leukemia

Functional Genomics and Computational Approaches Identify Novel Small Molecules Targeting Quiescent Leukemia Stem Cells

Optimizing Effects of mTOR Inhibition in Acute Myelogenous Leukemia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only